We pass the 200 employees milestone!

200 profiles that have chosen to join us. 200 backgrounds building up the multidisciplinary team that is our greatest strength.
Fast-growing, Trasis is becoming a major local employer and a world-renowned player in the Radiopharmaceutical industry
The Belgian economic press has taken a look at this extraordinary success story and outlined our progress in an article.

Read the article in French: https: La société liégeoise Trasis va doubler de taille d’ici trois ans

Key figures
A turnover of 33 million euros, a workforce that will double in the next 3 years, an annual increase in sales of 30 to 40% for almost a decade.
These are the indicators of Trasis’ development. Growth based mainly on a range of radiopharmacy solutions, a booming sector for healthcare.
Targeted diagnostics and cancer treatments are possible thanks to Trasis products used in nuclear medicine.

Customers all over the world
With 99% of export sales, Trasis succeeded in becoming a major actor in delivering solutions that meet the various needs between the production of radioactive isotopes and the injection to the patient. The company’s international customers include production centers, pharmaceutical companies, research centers and hospitals.

Investments
To support its growth, Trasis is self-sustaining and continues to invest in Research and Development, construction of new infrastructures, deployment of subsidiaries in the USA… Nothing is left to chance by the two founders, Gauthier Philippart and Jean-Luc Morelle, who together hold 95% of the shares.